Neuroinflammation in Alzheimer’s Disease: Current Therapeutic Approaches and Recent Progress Volume 4 - Issue 5

Rohit Shukla¹ and Tiratha Raj Singh^1,2*

• ¹Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology (JUIT), Waknaghat, Solan, Himachal Pradesh, India
• ²Centre for Excellence in Healthcare Technologies and Informatics (CEHTI), Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology, India

Received: November 24, 2020;   Published:December 09, 2020

Corresponding author: Tiratha Raj Singh, Associate Professor, Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology, Waknaghat, Solan, 173215, Himachal Pradesh, India

DOI: 10.32474/OJNBD.2020.04.000200

Abstract PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Alzheimer’s Disease (AD) is a progressive neurological disorder, characterized by amyloid-beta (Aβ) and neurofibrillary tangles (NFTs). Recently a new factor called neuroinflammation is added which can directly play a key role in the progression of AD. The recent studies in humans and mice had shown that aggregated protein (Aβ and NFTs) binds to the microglia cells (the resident innate immune cells) found in the central nervous system and activates the innate immune response which is characterized by the release of inflammatory mediators and increase the disease progression through the neuroinflammation. Several factors such as traumatic brain injury, obesity, etc. can play a major role in neuroinflammation. Hence targeting the immune mechanism and reduce the risk factors could lead to future promising therapeutics for AD.

Keywords: Alzheimer’s Disease; Neurofibrillary Tangles; Drug Development; Microglia; Neuroinflammation

Abstract| Introduction| Neuroinflammation in Alzheimer’s Disease| Potential Therapeutics for Neuroinflammation in AD| Conclusion and Future Perspective| Acknowledgement| References|